Home About USTH Find A USTH Doctor Contact Us      
Home - Services - General - Radiological Services
   About USTH
  Patient and Visitor
   For International
   Corporate Governance
   > Anatomic Pathology
   > Apolinario Mabini
        Rehabilitation Center
   > Clinical Pathology
   > Clinical
   > Outpatient
   > Pharmacy
   > Treatment Room
   > Radiological
     - CT Scan
     - Diagnostic
     - Magnetic
          Resonance Imaging
     - Nuclear Medicine
     - Ultrasound
 :: Special Services ::
 :: Pastoral Services ::
   Benavides Cancer
  Career Opportunity
  Find A USTH Doctor
   Contact Us
  What's New
NEW EQUIPMENT PROFILE The UST Hospital continues its aggressive equipment-updating program with these new acquisitions.
Our Services
Residency Training Application for the year 2016
Profiles of people who form part of our institution. Get to know your doctors, nurses, hospital administration and staff and other co-workers.
  CEO's Corner
Radiological Sciences

About Department of Radiological Science
CT Scan
Diagnostic Radiology
Magnetic Resonance Imaging
Nuclear Medicine

In the USTH Section of Nuclear Medicine, radionuclide administration is employed in both the diagnosis and treatment of disease.

The section prides itself in using one of the latest diagnostic nuclear medicine imaging machine: the Siemens Dual Head Gamma Camera. This machine is capable of doing SPECT acquisition aside from the usual planar images acquired from previous gamma cameras.

In diagnostic nuclear medicine, in-vivo physiologic or pathophysiologic patterns of radionuclide distribution are evaluated after the ingestion, injection, or inhalation, of selected radiopharmaceuticals. A qualitative or quantitative assessment can then be made of the function/s of a particular target organ.

Similarly, in-vitro measurements of radiolabelled chemicals used in radioimmunoassays are also assessed in the quantitative determination of specific serum hormone levels related to thyroid disease, such as thyroid stimulating hormone (TSH), free thyroxine (FT4), or thyroglobulin (Tg).

In therapeutic nuclear medicine, computed doses of beta-emitting radionuclides are given to patients in order to ablate targeted sites of disease. These include areas of functional thyroid disease or malignancy, metastases, or joint arthritides.

A team of well- trained personnel, consisting of physicians and nuclear technology staff, are responsible for the safe and efficient handling and dispensing of all radiopharmaceuticals, as well as for the operation of the section’s scintigraphic cameras and gamma counters. Each also adheres strictly to the principles of radiation protection and ensures that exposure to radioactivity is always as low as reasonably achievable (ALARA) principle.

The Section of Nuclear Medicine prides itself in the following

1. To provide the highest standard of patient care for all patients referred to the Section of Nuclear Medicine.

2. To address and service all patients' inquiries and requests promptly, professionally, ethically, and courteously.

3. To administer radiopharmaceuticals in diagnostic nuclear medicine, adhering to the highest standards of radiation safety and patient care, for the purpose of evaluating pathophysiologic processes in the diagnosis of disease.

4. To administer radiopharmaceuticals in therapeutic nuclear medicine, adhering to the highest standards of radiation safety and patient care, for the purpose of treating selected sites of functioning thyroid disease or malignancy, or joint arthritides.

5. To perform radioimmunoassays of selected serum hormones or components accurately maintaining the highest standard of radiation protection.

6. To safely isolate or store radioactive waste for a period of time amounting to at least 10 times the particular radioisotope's half-life, or till such time that measured radioactivity is equal to normal background radiation, at which time wastes will be disposed of properly.

7. To educate all persons regarding the benefits and dangers of radiation exposure and promote principles of radiation protection

8. To achieve as low as reasonably possible exposure of radiation to personnel, patients and public, from unsealed sources of radiation from the Section of Nuclear Medicine.

9. To limit maximum radiation exposure of all nuclear radiation personnel to 5 mSv/year averaged over 5 years, with no single annual exposure exceeding 20 mSv.

10. To limit maximum radiation exposure of the public and all non-radiation workers to 1 mSv/year averaged over 5 years, with no single annual exposure exceeding 5 mSv.

11. To upgrade the Section’s ancillary facilities and equipment in order to provide patients with the most modern services.

12. To continuously strengthen and enhance the skills and professionalism of the Section’s Medical, technical and non-technical staff, through in-section, inter-section and interhospital seminars and interactions, as well as through selective enrollment in local or international advanced/post-graduate skills and/or education programs.


While Nuclear Medicine allows the detection and evaluation of any disease entity affecting physiologic radiotracer uptake, it is limited by the availability and type of radiopharmaceutical employed. Depending on the nature of the radio-labelled chemical, different cells, tissues, or systems, will be targeted, and the manner by which radioactivity will consequently accumulate within them, will directly reflect on their physiologic or pathophysiologic action. Currently, assessments can be made on diseases altering iodine uptake in thyroidal tissues, the degree of cellular electro-gradation in relation to mitochondrial activity in cancer cells, cardiac cells, or glandular cells, glomerular filtration, renal cortical tubular function, osteoblastic activity, white blood cell activity, the integrity of the CNS, cellular glucose uptake, the integrity of the vascular system, hepatic polygonal or reticulo-endothelial uptake, and pulmonary perfusion or ventilation, among others. Thus, the section is able to employ radionuclides in the evaluation of thyroid disease, bone metastases, fracture or infection, cardiac perfusion, pulmonary perfusion and ventilation, hepatobiliary function, reticuloendothelial function, glomerular filtration rates, function of the renal cortex and patency of the urinary tract, and detection of functional Meckel’s diverticula or abdominal extravasation of blood.

Nuclear Medicine also offers treatment of diseases whose function allow uptake or localization of radiotracer, which should be limited only to areas of pathology. To date, radionuclides are used in the treatment of hyperthyroidism, functional thyroid carcinomas, palliation of intractable pain from bone metastases, therapy for hepatocellular carcinoma, and radiosynovectomy in patients suffering from synovitis.

Service Offered

NOTE : Due to complex patient preparation for indicated procedures, Please call +63 (02) 731 3001 Local 2354 for information.

A. In-Vivo diagnostic Procedures

    1. Bone Scintigraphy
  • 1.1. Bone scan
  • 1.2. Bone scan w/ 3 Phase
  • 1.3. Bone SPECT Scan
    2. Lung Scintigraphy
  • 2.1. Lung perfusion
  • 2.2. Lung Aerosol
  • 2.3. Lung perfusion w/ Aerosol
  • 2.4. Lung perfusion with Venography
  • 2.5. Venography with perfusion & aerosol
    3. Gastrointestinal Scintigraphy
  • 3.1. Tc-99m Pertechnetate for Meckel’s scan
  • 3.2. Tc-99m Labelled RBC’s for GI Bleeding
  • 3.3. Gastroesophageal Reflux (GER)
  • 3.4. Gastric Emptying Time (GET)
  • 3.5. Continuous Ambulatory Peritoneal Dialysis
  • 3.6. Liver scan
  • 3.7. Liver SPECT scan
  • 3.8. Hepatobiliary
    4. Renal Scintigraphy
  • 4.1. DMSA Renal scan
  • 4.2. DTPA Renal scan w/ In-Vitro Test
  • 4.3. Diuretic Renal scan w/ In-Vitro Test
  • 4.4. Captopril Pre & Post DTPA Renal scan
  • 4.5. Glomerular Filtration Rate (GFR) w/ In-Vitro Test
  • 4.6. Renal scan MAG 3
  • 4.7. Renal SPECT scan
    5. Cardiac Scintigraphy
  • 5.1. Thallium Stress scan
  • 5.2. Thallium scan (rest only)
  • 5.3. Thallium scan w/ dipyridamole
  • 5.4. Thallium re-injection
  • 5.5. Sestamibi stress scan
  • 5.6. Sestamibi scan (rest only)
  • 5.7. Sestamibi scan w/ dipyridamole
  • 5.8. Sestamibi express with exercise
  • 5.9. Sestamibi express pharmacologic
  • 5.10. Scan for myocardial infarct
    6. Endocrine Scintigraphy
  • 6.1. Thyroid Uptake & Scan
  • 6.2. Thyroid scan only
  • 6.3. Thyroid uptake only
  • 6.4. Thyroid scan w/ Tc-99m
  • 6.5. Thyroid scan w/ I-131
  • 6.6. Thyroid uptake w/ I-131
  • 6.7. Neck counting
  • 6.8. Whole body scan w/ I-131
  • 6.9. Whole body counting w/scan (Post RAI Therapy)
  • 6.10. Thallium Tc-99m Parathyroid
  • 6.11. MIBI Parathyroid
  • 6.12. MIBI Whole Body Scintigraphy for Thyroid CA
    7. CNS Scintigraphy
  • 7.1. Brain scan
  • 7.2. Brain SPECT scan w/ HMPAO
    8. Other Scintigraphy
  • 8.1. Salivary glands
  • 8.2. Testicular scan
  • 8.3. Gallium Whole body scan
  • 8.4. Sentinal Node imaging

B. In-Vivo or Radioimmunoassay Procedures

    1. Total T3
    2. Total T4
    3. TSH
    4. T3T4TSH pkg
    5. Free T3
    6. Free T4
    7. FT3FT4TSH pkg
    8. Thyroglobulin (Ag)
    9. Anti TG
    10. Anti TM (TPO)
    11. Urinary Iodide Excretion
    12. Neonatal T4
    13. Neonatal TSH

C. Radionuclide Therapy

  • I-131 Therapy for Hyperthyroidism
  • I-131 Ablation Therapy for Thyroid Carcinoma (CA)
  • Samarium 153 for palliation of metastatic bone pain
  • Radiosynovectomy for treatment of synovitis

Nuclear Medicine Section is located at the 2nd Floor UST Hospital, Private Division.

Operating Schedule / Service Hours
Nuclear Medicine Section is open from 7:00 a.m. – 5:00 p.m., Monday thru Friday and 7:00 a.m. – 3:00 p.m. on Saturday.